Fig. 3

Kaplan-Meier curves for progression-free survival. The median progression-free survival was 11.5 months (95% confidence interval [CI], 10.6–12.4) and 8.7 months (95% CI, 5.5–11.9) for the CB and CA groups, respectively. Statistically significant differences were observed in progression-free survival between groups. *The hazard ratio was calculated using a Cox proportional hazards model, with age, the site of primary tumour, the number of metastatic sites, and the performance status used as covariates and CB/CA therapy as the time-dependent factor. With respect to progression-free survival, the results of a log-rank test reported p = 0.000